[go: up one dir, main page]

EP0948325A2 - Lamotrigine in the treatment and prophylaxis of migraine - Google Patents

Lamotrigine in the treatment and prophylaxis of migraine

Info

Publication number
EP0948325A2
EP0948325A2 EP97953793A EP97953793A EP0948325A2 EP 0948325 A2 EP0948325 A2 EP 0948325A2 EP 97953793 A EP97953793 A EP 97953793A EP 97953793 A EP97953793 A EP 97953793A EP 0948325 A2 EP0948325 A2 EP 0948325A2
Authority
EP
European Patent Office
Prior art keywords
lamotrigine
migraine
pharmaceutically acceptable
treatment
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97953793A
Other languages
German (de)
French (fr)
Inventor
John Morris SmithKline Beecham Pharm. EVANS
Andrew SmithKline Beecham Pharm PARSONS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0948325A2 publication Critical patent/EP0948325A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Definitions

  • EP-0021121 (Buroughs Wellcome) describes a class of compounds which are described as being useful for the treatment and/or prevention of epilepsy.
  • One particular compound described therein is 3,5-diamino-6-(2,3-dichlorophenyl)-l,2,4-triazine which is better know as lamotrigine.
  • lamotrigine is particularly useful for treating and/or preventing migraine. Accordingly, the present invention provides the use of lamotrigine and/or pharmaceutically acceptable salts thereof in the manufacture of a medicament in the treatment and/or prevention of migraine.
  • Lamotrigine and/or pharmaceutically acceptable salts thereof may be prepared according to the procedures described in EP-0 021 121.
  • the administration to a sufferer in need thereof may be by way of oral (including sub-lingual) or parenteral administration.
  • a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50, 100, 200, 300 and 400 mg of the active compound.
  • Unit doses will normally be administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 1 to 500 mg, that is in the range of approximately 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg/day, for example 1 to 6 mg/kg/day.
  • lamotrigine is administered in the form of a unit-dose composition, such as a unit dose oral (including sub-lingual), rectal, topical or parenteral (especially intravenous) composition.
  • a unit dose oral (including sub-lingual), rectal, topical or parenteral (especially intravenous) composition Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories.
  • Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl jt?-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monoo
  • Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.
  • fluid unit dose forms are prepared containing the compound and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
  • the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
  • the present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of migraine which comprises lamotrigine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the invention provides a method for the treatment and/or prophylaxis of migraine which comprises administrating an effective or prophylactic amount of lamotrigine to a sufferer in need thereof.
  • compositions may be prepared in the manner as hereinbefore described.
  • the following pharmacological data demonstrates the present invention.
  • CSD was induced by administration of a small quantity (30 mg crystal) of KC1 to a region of the suprasylvian gyrus distant from recording electrodes, vessels under observation and other blood vessels.
  • KC1 dissolves slowly into the brain for the 6 min period of application.
  • the remaining KCl was washed from the brain surface with a saline swab. Changes in extracellular potential and in artery and vein diameter were then recorded for a period of up to 120 min.
  • the compound lamotrigine (10 mg/kg, i.p.) or vehicle (labrasol i.p.) was administered 90 min before CSD induction.
  • Bipolar stainless electrodes were stereotaxically placed into each trigeminal ganglion.
  • Guanethidine (3 mg/kg i.v.) was then administered and 45 min allowed for stabilisation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating or preventing migraine in humans comprises administering to a patient in need thereof an effective amount of lamotrigine or a pharmaceutically acceptable salt thereof.

Description

NOVEL TREATMENT
The present invention provides a new medical use of a known compound. EP-0021121 (Buroughs Wellcome) describes a class of compounds which are described as being useful for the treatment and/or prevention of epilepsy. One particular compound described therein is 3,5-diamino-6-(2,3-dichlorophenyl)-l,2,4-triazine which is better know as lamotrigine.
It has now been surprisingly found that lamotrigine is particularly useful for treating and/or preventing migraine. Accordingly, the present invention provides the use of lamotrigine and/or pharmaceutically acceptable salts thereof in the manufacture of a medicament in the treatment and/or prevention of migraine.
Lamotrigine and/or pharmaceutically acceptable salts thereof may be prepared according to the procedures described in EP-0 021 121. The administration to a sufferer in need thereof may be by way of oral (including sub-lingual) or parenteral administration.
An amount effective to treat the disorders hereinbefore described depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50, 100, 200, 300 and 400 mg of the active compound. Unit doses will normally be administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 1 to 500 mg, that is in the range of approximately 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg/day, for example 1 to 6 mg/kg/day.
It is greatly preferred that lamotrigine is administered in the form of a unit-dose composition, such as a unit dose oral (including sub-lingual), rectal, topical or parenteral (especially intravenous) composition. Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.
Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
These solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl jt?-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating. For parenteral administration, fluid unit dose forms are prepared containing the compound and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.
Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention. As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
The present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of migraine which comprises lamotrigine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
In a further aspect the invention provides a method for the treatment and/or prophylaxis of migraine which comprises administrating an effective or prophylactic amount of lamotrigine to a sufferer in need thereof.
Such compositions may be prepared in the manner as hereinbefore described. The following pharmacological data demonstrates the present invention.
Anti-Migraine Activity
Cortical Spreading Depression and Migraine
The above test as described by Wahl et al, 1987, Brain Research, 411, 72-80 may be used to determine the anti-migraine activity of compounds such as lamotrigine or pharmaceutically acceptable salts thereof.
Animal Preparation
Experiments were performed in female or male cats (2.5-3.0 kg) which were fasted overnight with free access to water. Anaesthesia was induced with 4-5% halothane and maintained by intravenous administration of α-chloralose (90-110 mg/kg). Rectal temperature, and acid base status were maintained within the physiological range. The right femoral artery and veins were cannulated for measuring of blood pressure, arterial blood sampling and drug administration, respectively. Heart rate was also determined from the blood pressure signal and recorded. A left sided parietal bone craniotomy and durectomy was performed and the brain covered with a layer of prewarmed mineral oil at 37°C. Changes in vessel diameter were investigated with intravital videomicroscopy and recorded on video tape.
Induction of Cortical Spreading Depression
CSD was induced by administration of a small quantity (30 mg crystal) of KC1 to a region of the suprasylvian gyrus distant from recording electrodes, vessels under observation and other blood vessels. As the brain is covered in a layer of warm mineral oil, the KC1 dissolves slowly into the brain for the 6 min period of application. Following this time, the remaining KCl was washed from the brain surface with a saline swab. Changes in extracellular potential and in artery and vein diameter were then recorded for a period of up to 120 min.
Drug Treatment
The compound lamotrigine (10 mg/kg, i.p.) or vehicle (labrasol i.p.) was administered 90 min before CSD induction.
KCl-induced reproducible CSD events in control animals (n=4) were monitored over the observation period. In contrast, in lamotrigine treated animals (n=2) only initial CSD events were detected in response to KCl application. The total median (min-max) number of CSD events in control and treated groups were 5.5 (4-9) and 2 (1-3), respectively.
Trigeminal nerve model in anaesthetised cats
In the model, adapted from that of Lambert G.A. et al (1984), J. Neurosurg. 61, 307-315, cats were anaethetised with α-chloralose (90-110 mg/kg i.v.) and artificially respired with room air. Body temperature was maintained at 37-38°C. A femoral artery was cannulated for recording of blood pressure and heart rate. Arterial blood flow was recorded by a Doppler flow probe placed around the right common carotid artery.
Bipolar stainless electrodes were stereotaxically placed into each trigeminal ganglion.
Guanethidine (3 mg/kg i.v.) was then administered and 45 min allowed for stabilisation.
Stimulation (2mA, 10 Hz for 2 min) of the trigeminal ganglion, ipsilateral to the carotid artery from which blood flow was measured, produced an increase in carotid blood flow and reduction in carotid vascular resistance. The ability of drugs, given intraduodenally to modulate this response was used to assess their effects on the trigemino-vascular system.
Intraduodenal administration of lamotrigine (10 mg/kg as 1% suspension in methylcellulose) produced a significant inhibition [34 + 8.7% (n=3)] of TGN-induced reduction in carotid vascular resistance after 3 hours.

Claims

1. Use of lamotrigine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment and/or prevention of migraine.
2. A method of treating or preventing migraine in humans which comprises administering to a patient in need thereof an effective amount of lamotrigine or a pharmaceutically acceptable salt thereof.
3. Use according to claim 1 or a method according to claim 2 wherein lamotrigine or a pharmaceutically acceptable salt thereof is administered in the form of a unit-dose composition.
4. A pharmaceutical composition for use in the treatment and/or prophylaxis of migraine which comprises lamotrigine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
EP97953793A 1996-12-12 1997-12-09 Lamotrigine in the treatment and prophylaxis of migraine Withdrawn EP0948325A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9625795 1996-12-12
GBGB9625795.1A GB9625795D0 (en) 1996-12-12 1996-12-12 Novel treatment
PCT/EP1997/006971 WO1998025594A2 (en) 1996-12-12 1997-12-09 Lamotrigine in the treatment and prophylaxis of migraine

Publications (1)

Publication Number Publication Date
EP0948325A2 true EP0948325A2 (en) 1999-10-13

Family

ID=10804309

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97953793A Withdrawn EP0948325A2 (en) 1996-12-12 1997-12-09 Lamotrigine in the treatment and prophylaxis of migraine

Country Status (5)

Country Link
EP (1) EP0948325A2 (en)
JP (1) JP2001510461A (en)
CA (1) CA2274858A1 (en)
GB (1) GB9625795D0 (en)
WO (1) WO1998025594A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1524981T3 (en) * 2002-07-29 2009-06-22 Glaxo Group Ltd Sustained-release compositions containing lamotrigine
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
FR2741879A1 (en) * 1995-12-05 1997-06-06 Esteve Labor Dr FLUOROPHENYL-TRIAZINE AND PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9825594A2 *

Also Published As

Publication number Publication date
JP2001510461A (en) 2001-07-31
CA2274858A1 (en) 1998-06-18
WO1998025594A2 (en) 1998-06-18
GB9625795D0 (en) 1997-01-29
WO1998025594A3 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
US5849763A (en) Use of levobupivacaine as an anesthetic agent
EP0173848B1 (en) Benzopyran compounds for use in the cardiovascular system
JPS6143113A (en) Medicinal composition
US4891380A (en) Novel treatment
CA2081344C (en) Use of 5-ht4 receptor antagonists in the treatment of arrythmias and stroke
EP0821588B1 (en) Levobupivacaine and its use as an anaesthetic in pregnant women
KR100443891B1 (en) Prevention and treatment of diabetic complications
US5049588A (en) Novel treatment for ischemia using an aminotetralin
JP2001515479A (en) Use of levobupivacaine or ropivacaine in the treatment of migraine
IE83342B1 (en) Use of a 5-HT4-receptor antagonists in the treatment of atrial fibrillation, including the prevention of stroke
EP0948325A2 (en) Lamotrigine in the treatment and prophylaxis of migraine
ES2235896T3 (en) USE OF RILUZOL FOR THE TREATMENT OF MULTIPLE SCLEROSIS.
US5162375A (en) Treatment of neuronal degeneration with 5HT1A agonists
HK1004523B (en) Use of 5-ht1a agonists for the manufacture of a medicament protecting against ischaemic damage
US5032596A (en) Treatment of disorders associated with pulmonary hypertension and/or right heart failure
CA2074039C (en) Antihypertensive combination
EP1740176A2 (en) Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives
KR20010021796A (en) Treatment and Prevention of Cardiac Disorders Using Selective Serotonin Re-uptake Inhibitors (SSRI)
CN115475165B (en) Application of indacaterol maleate in hemorrhagic brain injury related diseases
JP2003504396A (en) New uses of macrolide compounds
KR100413717B1 (en) Levobupicaine and its use as an anesthetic in pregnant women
KR950005869B1 (en) Therapeutic agent for gastritis
EP0723448A1 (en) Use of peniclorin for the treatment of posttherapeutic neuralgia
JPH0196133A (en) Cerebral blood flow improver
JPH03120219A (en) Composition for curing

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990611

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE ES FR GB IT LI NL

17Q First examination report despatched

Effective date: 20001108

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010519

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023067

Country of ref document: HK